Non-enzymatic glycation of human angiogenin: Effects on enzymatic activity and binding to hRI and DNA

Probing the effect of glycation on the pseudo-esterase activity of Human Serum Albumin

Human Serum Albumin (HSA), a major protein in blood plasma, exhibits pseudo-enzymatic activity such as pseudo-esterase activity. This study explores the impact of glycation on the pseudo-esterase activity of HSA. Glycation, a non-enzymatic reaction between reducing sugars and HSA was induced using glucose, fructose, and ribose. Glycated HSA samples (gHSA, fHSA, and rHSA) were analyzed for their pseudo-esterase activity using p-nitrophenyl acetate (PNPA) as a substrate. The kinetics of the enzyme-substrate reaction were studied, and structural changes monitored through UV-Vis, fluorescence, and circular dichroism (CD) spectroscopy. Glycation was confirmed using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-ToF) mass spectrometry. Results indicated a significant reduction in the pseudo-esterase activity of glycated HSA compared to native HSA. Ribose-induced glycation exhibited the highest reduction in activity, attributed to the higher glycation efficiency of ribose. Fluorescence studies revealed changes in Trp fluorescence, suggesting conformational alterations in glycated as well as acetylated HSA. CD spectroscopy confirmed secondary structural changes upon glycation, followed by acetylation. A binding study was conducted to deduce the effect of glycation and acetylation of HSA on its binding activity. These findings highlight the significance of understanding how glycation modifies the biochemical properties of HSA, impacting its physiological roles and therapeutic applications in metabolic disorders. Our studies specifically reveal that glycation impairs the pseudo-esterase activity and alters the drug-binding properties of HSA.

A Neglected Gene: The Role of the ANG Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease with a poor prognosis. To date, more than 40 ALS-related genes have been identified. However, there is still a lack of targeted therapeutic drugs for the treatment of ALS, especially for patients with acute onset and severe disease. A series of studies reported missense heterozygous mutations with loss of function in the coding region of the ANG gene in ALS patients. ANG deficiency is related to the pathogenesis of ALS, but the underlying mechanism has not been determined. This article aimed to synthesize and consolidate the knowledge of the pathological mechanism of ALS induced by ANG mutation and provide a theoretical basis for ALS diagnosis and targeted therapy. This article further delves into the mechanisms underlying the current understanding of the structure and function of the ANG gene, the association between ANG and ALS, and its pathogenesis. Mutations in ANG may lead to the development of ALS through the loss of neuroprotective function, induction of oxidative stress, or inhibition of rRNA synthesis. ANG mutations and genetic and environmental factors may cause disease heterogeneity and more severe disease than in ALS patients with the wild-type gene. Exploring this mechanism is expected to provide a new approach for ALS treatment through increasing ANG expression or angiogenin activity. However, the related study is still in its infancy; therefore, this article also highlights the need for further exploration of the application of ANG gene mutations in clinical trials and animal experiments is needed to achieve improved early diagnosis and treatment of ALS.